Comparative effectiveness of JAK inhibitors and biologic disease-modifying antirheumatic drugs in patients with rheumatoid arthritis

Soo Kyung Cho, Hyoungyoung Kim, Yeo Jin Song, Hye Won Kim, Eunwoo Nam, Shin Seok Lee, Hye Soon Lee, Sung Hoon Park, Yeon Ah Lee, Min Chan Park, Sung Hae Chang, Hyoun Ah Kim, Seung Ki Kwok, Hae Rim Kim, Hyun Sook Kim, Bo Young Yoon, Wan Sik Uhm, Yong Gil Kim, Jae Hoon Kim, Jisoo LeeJeongim Choi, Yoon Kyoung Sung

Research output: Contribution to journalArticlepeer-review

2 Scopus citations


Background/Aims: We aimed to compare the effectiveness and safety of Janus kinase inhibitors (JAKi) vs. biologic disease- modifying antirheumatic drugs (bDMARD) in Korean patients with rheumatoid arthritis (RA) who had an inadequate response to conventional synthetic DMARDs. Methods: A quasi-experimental, multi-center, prospective, non-randomized study was conducted to compare response rates between JAKi and bDMARDs in patients with RA naïve to targeted therapy. An interim analysis was performed to estimate the proportion of patients achieving low disease activity (LDA) based on disease activity score (DAS–28–erythroid sedimentation rate (ESR) (DAS28-ESR) at 24 weeks after treatment initiation and to evaluate the development of adverse events (AEs). Results: Among 506 patients enrolled from 17 institutions between April 2020 and August 2022, 346 (196 JAKi group and 150 bDMARD group) were included in the analysis. After 24 weeks of treatment, 49.0% of JAKi users and 48.7% of bDMARD users achieved LDA (p = 0.954). DAS28-ESR remission rates were also comparable between JAKi and bDMARD users (30.1% and 31.3%, respectively; p = 0.806). The frequency of AEs reported in the JAKi group was numerically higher than that in the bDMARDs group, but the frequencies of serious and severe AEs were comparable between the groups. Conclusions: Our interim findings reveal JAKi have comparable effectiveness and safety to bDMARDs at 24 weeks after treatment initiation.

Original languageEnglish
Pages (from-to)546-556
Number of pages11
JournalKorean Journal of Internal Medicine
Issue number4
StatePublished - Jul 2023

Bibliographical note

Publisher Copyright:
© 2023 The Korean Association of Internal Medicine.


  • Comparative effectiveness research
  • Janus kinase inhibitor
  • Rheumatoid arthritis
  • Safety
  • Tumor necrosis factor inhibitors


Dive into the research topics of 'Comparative effectiveness of JAK inhibitors and biologic disease-modifying antirheumatic drugs in patients with rheumatoid arthritis'. Together they form a unique fingerprint.

Cite this